Commentary: Antibiotic recommendations for acute otitis media and acute bacterial sinusitis in 2013 - The conundrum

Pediatric Infectious Disease Journal

Volumn 32, Issue 6, 2013, Pages 641-643

  Wald, Ellen R ^a   DeMuri, Gregory P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Acute bacterial sinusitis; Acute otitis media; Antimicrobials; Haemophilus influenzae; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN;

ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; AUDITORY TUBE; BACTERIAL SINUSITIS; HAEMOPHILUS INFLUENZAE; HISTORY; HUMAN; MIDDLE EAR PRESSURE; MORAXELLA CATARRHALIS; MYRINGOTOMY; NOTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; OTITIS MEDIA; SINUSITIS;

EID: 84879209427     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182868cc8     Document Type: Note

References (36)

1. American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics. 2001;108:798-808.
2. American Academy of Pediatrics. Subcommittee on Management of Acute Otitis M. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
3. Pichichero ME, Wright T. The use of tympanocentesis in the diagnosis and management of acute otitis media. Curr Infect Dis Rep. 2006;8:189-195.
4. Shaikh N, Hoberman A, Kearney DH, et al. Videos in clinical medicine. Tympanocentesis in children with acute otitis media. N Engl J Med. 2011;364:e4.
5. Wald ER, Milmoe GJ, Bowen A, et al. Acute maxillary sinusitis in children. N Engl J Med. 1981;304:749-754.
6. Wald ER, Reilly JS, Casselbrant M, et al. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr. 1984;104:297-302.
7. Parsons DS, Wald ER. Otitis media and sinusitis: similar diseases. Otolaryngol Clin North Am. 1996;29:11-25.
8. Wald ER. Acute otitis media and acute bacterial sinusitis. Clin Infect Dis. 2011;52(suppl 4):S277-S283.
9. Aspin MM, Hoberman A, McCarty J, et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr. 1994;125:136-141.
10. Hoberman A, Dagan R, Leibovitz E, et al. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J. 2005;24:525-532.
11. Marchant CD, Shurin PA, Turcyzk VA, et al. A randomized controlled trial of cefaclor compared with trimethoprim-sulfamethoxazole for treatment of acute otitis media. J Pediatr. 1984;105:633-638.
12. Pelton SI, Teele DW, Shurin PA, et al. Disparate cultures of middle ear fluids. Results from children with bilateral otitis media. Am J Dis Child. 1980;134:951-953.
13. Teele DW, Pelton SI, Klein JO. Bacteriology of acute otitis media unresponsive to initial antimicrobial therapy. J Pediatr. 1981;98:537-539.
14. Block SL, Hedrick JA, Kratzer J, et al. Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy. Pediatr Infect Dis J. 2000;19(suppl 12):S153-S158.
15. Block SL, McCarty JM, Hedrick JA, et al.; Cefdinir Otitis Media Study Group. Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 2000;19(suppl 12):S159-S165.
16. Arguedas A, Dagan R, Leibovitz E, et al. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J. 2006;25:211-218.
17. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298:1772-1778.
18. Pichichero ME, Casey JR, Hoberman A, et al. Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006. Clin Pediatr (Phila). 2008;47:901-906.
19. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J. 1992;11(suppl 8):S7-S11.
20. Joloba ML, Windau A, Bajaksouzian S, et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis. 2001;33:1489-1494.
21. Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother. 2007;51:4382-4389.
22. Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother. 2009;63:511-519.
23. Sahm DF, Brown N P, Draghi DC, et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008;120:8-15.
24. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
25. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829-833.
26. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304-309.
27. Critchley IA, Jacobs MR, Brown SD, et al. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother. 2008;52:2639-2643.
28. Kaplan SL; Pneumococcal Surveillance Group. Early trends for invasive pneumococcal infections in children following the introduction of the 13-valent pneumococcal conjugate vaccine. In: Infectious Disease Society of America; October 22, 2011. Boston, MA. Abstract LB-1.
29. Pichichero M, Casey J, Center K, et al. Efficacy of PCV13 in prevention of AOM and NP colonization in children: first year of data from the US. In: 8th International Symposium of Pneumococci and Pneumococcal Diseases. Iguacu Falls, Brazil; 2012.
30. Block SL, Doern G V, Pfaller MA. Oral beta-lactams in the treatment of acute otitis media. Diagn Microbiol Infect Dis. 2007;57(suppl 3):19S-30S.
31. Centers for Disease C, Prevention. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months - selected U.S. regions, 2010-2011. MMWR Morb Mortal Wkly Rep. 2011;60:1477-1481.
32. Fallon RM, Kuti JL, Doern G V, et al. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs. 2008;10:329-335.
33. Pelton SI, Loughlin A, Marchant C, et al. Indirect effects of PCV13 on nasopharyngeal colonization with Streptococcus pneumoniae vaccine serotypes acheived with 65% to 75% vaccine uptake. In: IDWeek. San Diego, CA; 2012.
34. Tähtinen PA, Laine MK, Huovinen P, et al. A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med. 2011;364: 116-126.
35. Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. N Engl J Med. 2011;364: 105-115.
36. Wald E, Nash D, Eickhoff J. Effectiveness of amoxicillin-clavulanate potassium in the treatment of acute bacterial sinusitis in children: a double-blind, placebo-controlled trial. Pediatrics. 2009;124:9-15.